



Iowa Department of Human Services

Kim Reynolds
Governor

Adam Gregg
Lt. Governor

Jerry R. Foxhoven
Director

Iowa Medicaid Drug Utilization Review (DUR) Commission Meeting

December 6, 2017

**Location: Learning Resource Center
3550 Mills Civic Parkway
West Des Moines, Iowa, 50265
Fairmeadows Room**

Time: 9:30 a.m. – 1:30 p.m.

Final Agenda

1. Welcome & Introductions
 - a) Commission Members and Staff
2. Commission Business
 - a) Approval of the Minutes
 - b) DHS Recommendation Letter – October 2017
 - c) P & T Recommendation Letter – November 2017
3. IME Pharmacy Update
4. Fee-for-Service Program Prevalence Report Summary
5. MCO Prevalence Report Summary and Updates
 - a) Amerigroup
 - b) United Healthcare Community Plan
6. Public Comment* (See Conflict of Interest Disclosure Form)
7. Prior Authorization
 - a) Buprenorphine/Naloxone – Initial Review
 - b) Smoking Cessation Therapy, Oral & Nicotine Replacement Therapy – Initial Review
 - c) Angiotensin Receptor Blocker Before ACE Inhibitor – Removal of Criteria
 - d) Immunomodulators, Topical – Initial Review
 - e) Ivacaftor (Kalydeco) – Initial Review
 - f) Lidocaine Patch – Initial Review
 - g) Topical Acne and Rosacea Products – Initial Review
 - h) Biologicals for Ankylosing Spondylitis – Second Review

- i) Biologicals for Arthritis – Second Review
- j) Biologicals for Inflammatory Bowel Disease – Second Review
- k) Biologicals for Plaque Psoriasis – Second Review
- l) Tramadol or Codeine in Members < 18 – Second Review
- m) Sacubitril/Valsartan (Entresto) - Second Review

8. Miscellaneous

- a) DUR Digest Vol. 30, No. 2 – Initial Review
- b) MedWatch
- c) Articles of Interest
 - i. Cash-only Suboxone clinics fuel fears of new ‘pill mills”
<http://www.dispatch.com/news/20171008/cash-only-suboxone-clinics-fuel-fears-of-new-pill-mills/1>

9. Adjournment

*Individuals attending meetings of the DUR Commission shall have an opportunity to address the Commission. This opportunity will be granted once during the open portion of the meeting. In order to accommodate all interested parties, all speakers are requested to limit their comments to **5 minutes or less**. If you represent a drug manufacturer as an employee, as a contractor, as a member of the manufacturer's Speaker Bureau, or by any other means, we expect you to cover your individual product or entire product line in that five-minute time frame. Speakers who represent multiple manufacturers will share their 5 minutes with the other manufacturer representative(s) whose product they are speaking on.

www.iadur.org

For more information, contact the DUR Project Coordinator, Pamela Smith, R.Ph., at info@iadur.org or (515) 974-3131

*****Next Meeting February 7, 2018***
Learning Resource Center
3550 Mills Civic Parkway, West Des Moines, IA**